China News Service, Beijing, August 13 (Reporter Sun Zifa) A new research paper published in Springer Nature's professional academic journal "Nature-Medical" stated that a clinical trial evaluating combined immunotherapy for the treatment of metastatic lung cancer Studies have shown that the combination of two immunotherapies-immune checkpoint inhibitors and adoptive immune cell therapy using tumor-infiltrating lung lymphocytes, activates an anti-tumor response in patients with metastatic lung cancer
The paper believes that the inclusion of 20 participants’ proof-of-concept data may provide new treatments for patients with worsening lung cancer
According to reports, in immune checkpoint inhibitor therapy, drugs are used to suppress protein regulation of the immune system, but they can only produce clinical responses in some cancer patients
The corresponding author of the paper, Benjamin Creelan (Benjamin Creelan) of the H.
Through molecular analysis of TILs and genetic sequencing of tumor biopsies, the authors of the paper determined that the response observed in most patients was related to the recognition of antigens expressed by tumor cells by TILs
The author of the paper believes that although the number of patients participating in the preliminary trial is small, this combination therapy may constitute a promising new treatment strategy to help patients with advanced disease
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
